REFERENCES
  1. World Health Organization. Coronavirus disease (COVID-19) pandemic. 2020. https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov. Accessed 10 July, 2020.
  2. World Health Organization. Coronavirus disease (COVID-2019) situation reports-173. Geneva: WHO; 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200711-covid-19-sitrep-173.pdf?sfvrsn=949920b4_2. Accessed 11 July, 2020.
  3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med . 2020;46(5):846-848.
  4. Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut Med . 2020:1-9.
  5. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy [JAMA Network]. https ://jaman etwor k.com/journ als/jama/fulla rticl e/27636 67. Accessed 29 April, 2020.
  6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet . 2020;395(10223):507‐513.
  7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020;395(10223):497‐506.
  8. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol . 2020;92(7):814-818.
  9. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol . 2015;16(5):448-457.
  10. Wang WK, Chen SY, Liu IJ, et al. Severe Acute Respiratory Syndrome Research Group of the National Taiwan University College of Medicine/NTU Hospital. Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome. Clin Infect Dis . 2004;39(7):1071-1075.
  11. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet . 2020;395(10223):e30-e31.
  12. Cingolani A, Tummolo AM, Montemurro G, et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection . 2020:1-5.
  13. Kubo S, Nakayamada S, Sakata K, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system.Front Immunol . 2018;9:1510.
  14. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect . 2020:S0163-4453(20)30228-0.
  15. Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in COVID-19 patients. 2020. https://doi.org/10.1101/2020.06.26.20135319
  16. World Health Organization. Clinical management of COVID-19. Interim guidance. 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed 21 July, 2020.
  17. Archer SL, Sharp WW, Weir EK. Differentiating COVID-19 pneumonia from acute respiratory distress syndrome and high altitude pulmonary edema.Circulation . 2020;142(2):101-104.
  18. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol . 2008;26(1):127-132.
  19. Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI Patients. Clin Pharmacol Ther . 2018;104(2):364-373.
  20. McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther . 2019;21(1):183.
  21. Perricone C, Triggianese P, Bartoloni E, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun . 2020;111:102468.